Randomized trial shows Vitamin C supplementation linked to improved survival in blood disorder patients — Evidence Review
Published in Cancer, by researchers from Van Andel Institute, Stand Up To Cancer, Rigshospitalet, Copenhagen University Hospital
Researched by
— the AI search engine for science
Table of Contents
A new phase 2 clinical trial found that vitamin C supplementation was associated with fewer deaths among people with early-stage blood disorders, though more research is needed to confirm these findings. Previous large reviews of vitamin C’s effects on mortality and cancer risk have shown mixed results, with some supporting benefits from higher dietary intake but not from supplements, and others finding little or no impact on survival.
- While this new trial suggests a possible survival benefit of vitamin C in people with certain blood disorders, most earlier meta-analyses and systematic reviews report limited or no effect of vitamin C supplementation on cancer or all-cause mortality, especially in critically ill or cancer patients 1 4 5 12 13.
- Some studies indicate that higher vitamin C intake from foods, not supplements, is linked to reduced risk of cardiovascular disease and cancer, but do not recommend supplements for disease prevention 1.
- Evidence for vitamin C’s benefit in cancer or blood disorder settings is inconclusive, with prior research highlighting safety but inconsistent survival advantages, and raising possible risks with high-dose intravenous vitamin C in specific patient populations 9 12 13.
Study Overview and Key Findings
Research into non-toxic, widely available treatments for blood cancers and precancerous blood disorders is ongoing, especially as new insights emerge about how nutrients like vitamin C may interact with cellular processes and disease pathways. This new phase 2 randomized controlled trial, conducted across Denmark and the United States, investigated whether daily oral vitamin C supplementation could improve outcomes for patients with clonal cytopenia of undetermined significance (CCUS) or lower-risk myeloid malignancies—conditions that can precede or represent early forms of blood cancer. The study is notable because it focuses on a relatively understudied patient population and explores vitamin C’s impact on both molecular and clinical outcomes, including overall survival.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | Van Andel Institute, Stand Up To Cancer, Rigshospitalet, Copenhagen University Hospital |
| Journal Name | Cancer |
| Authors | Stine Ulrik Mikkelsen, Ali Al-Mousawi, Amalie Bach Puglisi, Anders Pommer Vallentin, Astrid Østergaard Mortensen, Zachary Madaj, Toshinori Hinoue, Heidi Naomi Ottesen, Jakob Schmidt Jespersen, Linn Gillberg, Morten Tulstrup, Niels Richard Hansen, Jakob Werner Hansen, Mette Klarskov Andersen, Stacey Lyn Thomas, Christine Isaguirre, Ryan Sheldon, Marie Adams, Ryan Burgos, Stephen Baylin, Bo Kok Mortensen, Casey Lee O’Connell, Marianne Tang Severinsen, Peter William Laird, Jens Lykkesfeldt, Peter Jones, Kirsten Grønbæk |
| Population | People with precancerous blood conditions or low-risk blood cancers |
| Sample Size | n=109 |
| Methods | Randomized Controlled Trial (RCT) |
| Outcome | Survival rates and health problems among participants |
| Results | Vitamin C group had 11 deaths vs. 24 in placebo group |
Literature Review: Related Studies
To better understand how the new findings fit into the broader context of vitamin C research, we searched the Consensus database, which contains over 200 million scientific papers. The following search queries were used:
- vitamin C supplements mortality outcomes
- blood disorder treatment vitamin C effects
- placebo comparison vitamin C survival rates
| Topic | Key Findings |
|---|---|
| Does vitamin C supplementation reduce mortality in cancer or chronic disease patients? | - Most meta-analyses and systematic reviews find little or no evidence that vitamin C supplements lower all-cause or cancer-specific mortality, especially in critically ill or cancer patients 1 4 5 12 13. - Higher vitamin C intake from food, not supplements, may be associated with lower disease risk and mortality 1. |
| What are the clinical effects of vitamin C in blood or hematological disorders? | - Vitamin C supplementation may have limited benefit as an adjunct to oral iron in anemia, with only minor improvements in hemoglobin and little effect on clinical outcomes 8. - There is emerging evidence for potential immunomodulatory and anti-inflammatory effects in hematological neoplasms, but robust clinical data are lacking 10. |
| How does vitamin C impact outcomes in critically ill or hospitalized patients? | - Vitamin C given intravenously does not consistently improve survival in ICU, sepsis, or critical illness, and may sometimes increase risk in certain populations 2 3 4 5 11. - Some studies report reduced vasopressor use or ventilation needs, but not improved overall survival 3. |
| Are there risks or adverse effects of high-dose vitamin C in cancer patients? | - Intravenous gram-dose vitamin C may increase thrombosis risk in cancer patients due to procoagulant effects on red blood cells, particularly at very high doses 9. - Most reviews report that vitamin C is generally safe, with few side effects at standard or moderate dosages 12 13. |
Does vitamin C supplementation reduce mortality in cancer or chronic disease patients?
The new trial's finding of reduced mortality among vitamin C recipients contrasts with the bulk of meta-analyses and systematic reviews, which generally report no significant impact of vitamin C supplementation on all-cause or cancer-specific mortality in most populations. Notably, benefits seen in observational studies often reflect higher dietary (food) intake rather than supplement use. Some studies suggest possible benefits in specific subgroups, but conclusive evidence is lacking.
- Large meta-analyses have found that higher dietary, but not supplemental, vitamin C intake correlates with reduced cardiovascular, cancer, and all-cause mortality 1.
- Multiple systematic reviews in cancer and critical illness settings report little or no impact of vitamin C supplements on survival 4 5 12 13.
- Some evidence suggests intravenous vitamin C may improve progression-free survival in certain cancers when combined with chemotherapy, but effects on overall survival remain unclear 13.
- The current study’s findings, if confirmed, would represent an exception to the broader trend of neutral mortality results in supplementation trials 1 4 5 12 13.
What are the clinical effects of vitamin C in blood or hematological disorders?
The current trial addresses a gap in research by focusing on early-stage blood disorders. Previous studies on vitamin C in hematology have mostly centered on its role in iron absorption and immune modulation, with limited data on survival or disease progression in neoplastic blood conditions.
- Systematic review of vitamin C plus oral iron in anemia shows only minor, likely clinically insignificant, improvements in hemoglobin 8.
- Literature reviews indicate potential for vitamin C to modulate inflammation, cytokine environment, and immune response in autoimmune and hematological diseases, but robust clinical outcome data are scarce 10.
- The new study’s findings of fewer deaths and possible anti-inflammatory effects in vitamin C recipients warrant further exploration in larger trials 10.
- There is emerging mechanistic support for vitamin C’s role in gene regulation and enzyme function in blood disorders, but clinical outcome data are still limited 10.
How does vitamin C impact outcomes in critically ill or hospitalized patients?
Several meta-analyses and randomized trials have tested vitamin C in the context of critical illness, sepsis, or ICU care. Results have been largely neutral, with some studies suggesting possible harm at high intravenous doses in specific populations.
- Systematic reviews and meta-analyses consistently report no significant reduction in mortality with vitamin C supplementation in critically ill, ICU, or sepsis patients 2 3 4 5 11.
- Some studies note minor improvements in secondary outcomes (e.g., reduced vasopressor use or mechanical ventilation), but not survival 3.
- One large RCT found increased risk of death or persistent organ dysfunction with intravenous vitamin C in sepsis 11.
- These findings highlight the importance of patient selection, dosing, and route of administration in vitamin C research 2 3 4 5 11.
Are there risks or adverse effects of high-dose vitamin C in cancer patients?
While vitamin C is generally considered safe, some evidence points to potential risks at high intravenous doses, particularly for cancer patients. Most reviews indicate low toxicity at standard oral doses, but rare adverse effects and theoretical risks warrant caution.
- Experimental research suggests that very high (gram-dose) intravenous vitamin C can increase thrombosis risk in cancer patients due to procoagulant activation of red blood cells 9.
- Most clinical reviews report vitamin C supplementation is safe and well-tolerated, with few adverse events at moderate doses 12 13.
- The new phase 2 trial noted more gastrointestinal issues in the vitamin C group, but fewer serious complications like anemia, pneumonia, or internal bleeding [news article].
- Careful monitoring of dose and administration route is important, especially when considering vitamin C in vulnerable or high-risk patient groups 9 12 13.
Future Research Questions
Despite promising signals, the new trial’s findings must be interpreted with caution due to its small sample size and exploratory nature. Larger, well-powered studies are necessary to confirm whether vitamin C supplementation can meaningfully improve survival or prevent disease progression in patients with early-stage blood disorders or related cancers. Additionally, further research is needed to clarify mechanisms, optimal dosing, and patient selection, as well as to assess possible risks and benefits in broader populations.
| Research Question | Relevance |
|---|---|
| Does vitamin C supplementation improve overall survival in patients with early-stage blood disorders? | This question addresses whether the observed survival benefit in the phase 2 trial can be replicated in larger, diverse populations—a critical step before recommendations can be made 1 4 5 12 13. |
| What is the mechanism by which vitamin C affects gene regulation and disease progression in hematological malignancies? | Mechanistic studies could help explain the biological basis for clinical effects, such as modulation of TET enzymes and inflammatory pathways, and guide targeted therapies 10. |
| Are there subgroups of patients with blood disorders who benefit more from vitamin C supplementation? | Identifying patient subgroups (e.g., based on genetic mutations, baseline vitamin C status, or disease characteristics) could optimize therapy and avoid unnecessary supplementation 7 8 12. |
| What are the long-term risks and side effects of oral and intravenous vitamin C in cancer patients? | Understanding potential harms, such as thrombosis or gastrointestinal issues, is essential, especially as some studies suggest possible adverse effects with high-dose intravenous vitamin C 9 12 13. |
| Does vitamin C supplementation affect disease progression or transformation to leukemia in patients with clonal cytopenia? | This question explores whether vitamin C can prevent or delay progression from precancerous blood conditions to more severe malignancies, a major clinical goal in hematology 10. |